

PATTERN OF PATHOGENS IN EAR DISCHARGE OF HIV- INFECTED CHILDREN IN NNEWI, SOUTHEAST NIGERIA

*E. F. Ugochukwu, *C. C. Ezechukwu, **N. Undie, ***C. Akujobi

*Department of Paediatrics, ** Otorhinolaryngology and *** Medical Microbiology Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria

ABSTRACT

Objective: This is a descriptive, prospective, hospital-based study designed to determine the prevalent organisms in ear infections and their antimicrobial susceptibility patterns in HIV-infected children compared to age- and sex-matched HIV sero-negative patients.

Method: Two hundred and fifty eight HIV-infected children being followed up at the Paediatric HIV clinic had their ears examined for middle ear infection. All those with discharging ears had swabs taken. Culture and antimicrobial sensitivities were ascertained. The same was done for another cohort of 57 age- and sex-matched HIV-negative patients with discharging ears.

Results: Twenty eight (10.9%) of 258 HIV-infected children had discharging ears and were made up of 13 females and 15 males aged between 7 and 132 months. Out of this number 85.7% had chronically discharging ears. 96.4% of the 28 children acquired the HIV infection vertically. 78.6% had been on antiretroviral drugs from one to twenty-one months. 67.9% of the patients had associated opportunistic infections. Acute ear infections were predominant among the control group. *Klebsiella*, *Proteus*, *Staphylococcus* and *Pseudomonas* were major pathogens isolated among the HIV-infected group and *Streptococcus*, *Klebsiella* and *Pseudomonas* for the HIV-negative group. A hundred percent sensitivity was recorded among the quinolones for all bacterial organisms isolated.

Conclusion: HIV-infected children tend to have more of chronic than acute ear infections and this is reflected in the causative organisms. Similar antimicrobial sensitivity patterns apply to HIV-infected and HIV-negative children. There is a need to revisit the use of quinolones in children.

Key Words: Ear Infection, HIV, Children.

(Accepted 13 August 2006)

BACKGROUND

Human immunodeficiency virus (HIV) infection continues to be a vexing problem in the paediatric population. Otitis media, a common entity in immunocompetent as well as immunocompromised children, is prevalent in paediatric patients with HIV infection.^{1,2} Recurrent infections and complications secondary to otitis media are also common in this population.³

Suppurative otitis media is more common in HIV-infected children in the first year of life. By age 3 years, most HIV-infected children will have had one or more episodes of acute otitis media. Signs and symptoms are similar to those in other children. Chronic suppurative otitis media occurs with increased frequency in HIV-infected children and is

associated with painless, chronic ear discharge and a perforated ear drum.

Studies from centers in Nigeria⁴⁻⁷ and other countries in Africa,⁸⁻¹¹ implicate *Staphylococcus aureus*, *Streptococcus pneumoniae* and *Haemophilus influenzae* among other isolates in acute otitis media, while *Pseudomonas species*, *Proteus* and *Staphylococcus aureus* were responsible for chronic otitis media

INTRODUCTION

Middle ear infections (otitis media) are the second most common disease of childhood, after upper respiratory infections.¹² Acute otitis media is a recurrent disease, more than one third of children experiencing six or more episodes of acute otitis media by age seven years.¹² This disease is common in children due to their shorter and more horizontal Eustachian tubes, with smaller orifices, and less supporting cartilage when compared to those of

Adults Mucosal inflammation and oedema due to viral upper respiratory infection further impair middle ear drainage and interfere with host defenses. These cumulatively predispose children to developing acute otitis media.¹³ Chronic suppurative otitis media is a chronic inflammation of the middle ear that persists for at least 6 weeks. Both types of otitis media may be associated with otorrhoea through a perforated tympanic membrane.

Early B-cell antibody dysfunction disproportionately affects children who have not generated a repertoire of antibodies protective against common bacteria before onset of HIV-induced helper T-cell dysfunction.¹⁴ Consequently, recurrent infections such as otitis media, sinusitis and pneumonia caused by bacteria like *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Staphylococcus aureus*, have been reported as characteristic of paediatric HIV disease.¹⁵

Neutropenia, caused by HIV infection or antiviral therapy, may also produce mucositis, causing Eustachian tube dysfunction. Likewise, pharyngeal lymphoid hyperplasia associated with HIV infection, may extrinsically obstruct or infiltrate the Eustachian tube.¹⁶ Abnormal local and systemic immunity, characteristic of advanced HIV infection, would reasonably be considered to account, at least in part, for the predilection to recurrent and persistent otitis media among children with symptomatic HIV infection.

Barnett et al¹⁷ reported that abnormally low CD4 lymphocyte counts were associated with significantly greater mean numbers of episodes of acute otitis media during the first year of life and an increased risk for recurrent otitis media. Likewise, Chen et al¹⁸ reported that the frequency of recurrent otitis media increased as the clinical and immunologic status of patients with HIV worsened.

This study was therefore designed to

- 1 Determine the prevalent organisms in ear infections, and their antimicrobial susceptibility patterns in HIV -infected children presenting to Nnamdi Azikiwe University Teaching Hospital, Nnewi, and to

- 2 Ascertain differences, if any, between the above group of patients and their age- and sex- matched HIV sero-negative counterparts.

SUBJECTS AND METHODS

Two hundred and fifty-eight HIV-infected patients being followed up in the Paediatric HIV clinic of the Nnamdi Azikiwe University Teaching Hospital, Nnewi, were examined for ear infections during the study period (June 1 to December 31, 2005). Twenty-eight had discharging ears and had ear swabs collected from them. Associated data on gender,

route of infection, whether on antiretroviral (ARV) drugs, duration and frequency of ear discharge, CD4 count, absolute lymphocyte count and presence of opportunistic infections, were also obtained. Myringotomy was not done.

Concurrently, age- and sex-matched HIV-negative children with discharging ears were also recruited at the ENT clinic as controls (HIV status of patients is routinely obtained, after pre-test counseling, before any surgical procedures are embarked on). These also had ear swabs obtained, in addition to data on age, gender, duration and frequency of ear discharge and absolute lymphocyte count. Consent was sought and obtained from parents and/or guardians before recruitment in the study.

The ear swab specimens were processed and identified using conventional methods. *Escherichia coli* ATCC 25922 and *Staphylococcus aureus* ATCC 29213 were included as control strains. The antimicrobial agents used for susceptibility testing included: ceftazidime (30µg), ciprofloxacin (5µg), sparfloxacin (5µg), ofloxacin (5µg), cefuroxime (30µg), erythromycin (15µg), doxycycline (25µg), pefloxacin (30µg), cefotaxime (30µg), amoxicillin-clavulanic acid (30µg), gentamicin (10µg), and chloramphenicol. All were oxoid products.

Antimicrobial susceptibility testing was done by the disk diffusion method on Mueller-Hinton agar (Difco laboratories, Detroit Michigan). The inoculum's turbidity was standardized to 0.5 MacFarland standards. Results were interpreted according to NCCLS criteria.¹⁹

Statistical analysis was done with the SPSS statistical package. The chi-square test was used and the 0.05 level of significance was adopted.

RESULTS

Out of a total of 258 HIV-infected children presenting at the Paediatric HIV clinic during the study period, 28 (10.9%) had discharging ears. They were made up of 13 females (46.4%) and 15 males (53.6%), aged 7-132 months, with an M: F ratio of 1.1: 1. (See Table 1). Twenty-seven (96.4%) acquired the virus vertically and one (3.6%) via blood transfusion.

Twenty-two (78.6%) had been on ARV drugs (for varying durations of one to twenty-one months) in the following combinations: nevirapine, lamivudine and zidovudine (10, 35.7%); nevirapine, lamivudine and stavudine (9, 32.1%); nelfinavir, lamivudine and zidovudine (2, 7.1%); efavirenz, lamivudine and stavudine (1, 3.6%). Six patients (21.4%) were not on any ARV drugs. Nevirapine was initiated at 4mg/kg once daily for the first two weeks, then twice daily at same dose for children above 8 years, while those below 8 years were placed on 7mg/kg twice daily

At same dose for children above 8 years, while those below 8 years were placed on 7mg/kg twice daily after the first two weeks. Lamivudine was given at the dose of 4mg/kg twice daily; Zidovudine 240mg/m² body surface area twice daily; Stavudine 1mg/kg twice daily; Nelfinavir 60mg/kg twice daily and Efavirenz for age > 3 years as a single daily dose as follows: 10 - <15kg 200mg, 15 - <20kg 250mg, 20 - <25kg 300mg, 25 - <33kg 350mg and 33 - <40kg 400mg. Twenty-four (85.7%) had chronically discharging ears while 4 (14.3%) had recurrent otitis media. There were associated opportunistic infections in 19 children (67.9%). These included tuberculosis, oral candidiasis, diarrhoeal disease, herpes zoster and facial flat warts.

Table 2 outlines the bacterial organisms isolated from the discharging ears while Table 3 gives the

antibiotic sensitivity pattern of isolates from subjects and controls. A hundred percent sensitivity was recorded among the quinolones for all bacterial organisms isolated. All patients received appropriate antimicrobial and ancillary therapies for otitis media. Among the control group 33 (58.0%) had acute otitis media, 21 (36.8%) had chronic otitis media while 3 (5.2%) had recurrent ear infections. It has been suggested that in centers where the CD4 lymphocyte counts cannot be obtained the absolute lymphocyte count could be used as a guide to the level of immunosuppression.²⁰ Table 4 compared the absolute lymphocyte counts as immunologic categories between test and control subjects. Absolute lymphocyte counts falling within the normal range did not rule out immunosuppression as is shown in Table 5 where the true immunological status as given

Table 1: Age and sex distribution for cohort and control groups

| Age in months | Males (Test group) | Males (Control group) | Females (Test group) | Females (Control group) |
|---------------|-----------------------|--------------------------|-------------------------|----------------------------|
| <18 | 5 (17.9) | 6 (10.5) | 4 (14.3) | 4 (7.0) |
| 18-60 | 8 (28.6) | 11 (19.3) | 5 (17.8) | 8 (14.0) |
| >60 | 2 (7.1) | 16 (28.1) | 4 (14.3) | 12 (21.1) |
| Total | 15 (53.6) | 33 (57.9) | 13 (46.4) | 24 (42.1) |

Proportions as percentages are in parentheses
p=0.001737

Table 2: Bacterial isolates from the ears of patients

| Organism isolated | No. of Test patients | No. of Control patients |
|-----------------------|----------------------|-------------------------|
| Streptococcus spp | 0 (0.0) | 31 (53.8) |
| Klebsiella spp | 7 (25.0) | 9 (15.4) |
| Proteus spp | 7 (25.0) | 4 (7.7) |
| Pseudomonas spp | 5 (17.9) | 9 (15.4) |
| Escherichia coli | 2 (7.1) | 0 (0.0) |
| Staphylococcus aureus | 7 (25.0) | 0 (0.0) |
| No bacterial growth | 0 (0.0) | 4 (7.7) |
| Total | 28 (100.0) | 57 (100.0) |

Table 3: Antibiotic sensitivity pattern of bacterial isolates from subjects and controls

| Antibiotic | Streptococcus | Klebsiella | Proteus-s | E.coli | Pseudomonas | Staph aureus |
|-----------------|---------------|------------|-----------|--------|-------------|--------------|
| Ceftazidime | - | - | - | - | - | - |
| Ciprofloxacin | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| Ofloxacin | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| Sparfloxacin | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| Cefuroxime | - | - | - | - | - | - |
| Erythromycin | 75.0 | 28.6 | - | - | 50.0 | 66.7 |
| Doxycycline | - | 28.6 | 33.3 | - | - | - |
| Pefloxacin | - | - | - | 100.0 | - | 33.3 |
| Cefotaxime | - | - | - | - | - | - |
| Co-amoxiclav | - | - | - | - | - | - |
| Gentamicin | - | 14.3 | 33.3 | 100.0 | - | 66.7 |
| Chloramphenicol | - | 14.3 | - | - | - | - |
| Amoxicillin | - | 14.3 | - | 100.0 | - | - |
| Cotrimoxazole | - | - | 33.3 | - | - | 33.3 |
| Cephalexin | - | - | - | - | - | 33.3 |
| Clindamycin | - | 14.3 | - | - | - | 66.7 |
| Streptomycin | - | 14.3 | - | - | - | 33.3 |
| Rifampicin | 50 | - | - | - | - | 33.3 |

Proportions are percentages of cultures where the drug is sensitive
 '-' connotes not tested or resistant

Table 4: Comparison of lymphocyte counts

| Total lymphocyte count [cells/ μ L] | No. of children aged < 18 months Months | No. of children aged 18-60 months | No. Of children aged > 60 months |
|---|---|---|--|
| > 3500 Not immunosuppressed | Test 9 (31.6) Control 6 (57.1) | | |
| < 3500 Immunosuppressed | Test 1 (5.2) Control 4 (42.9) | | |
| > 2300 Not immunosuppressed | | Test 12 (42.1) Control 15 (80.0) | |
| < 2300 Immunosuppressed | | Test 0 (0.0) Control 4 (20.0) | |
| > 1200 Not immunosuppressed | | | Test 6 (21.1) Control 35 (90.9) |
| < 1200 Immunosuppressed | | | Test 0 (0.0) Control 3 (9.1) |

Proportions as percentages are in parentheses

Table 5: Immune status of the cohort under study according to their CD4 counts and percentages

| Immune status | Age up to 12 Months | Age 13 59 months months | Age 60 months and over |
|-----------------------------------|---------------------|-------------------------|------------------------|
| Not significant immunosuppression | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Mild immunosuppression | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Advanced immunosuppression | 1 (3.6) | 6 (21.4) | 1 (3.6) |
| Severe Immunosuppression | 7 (25.0) | 9 (32.1) | 4 (14.3) |
| Total | 8 | 15 | 5 |

Proportions as percentages are in parentheses

DISCUSSION

Recurrent or persistent otitis media is one of the recognized features of HIV infection in children.^{20, 21} This is consequent on the attendant immune suppression encountered in HIV infection.^{1, 2, 22} In the study 10.9% of 258 HIV infected children presented with recurrent/persistently discharging ears. This finding has been documented in a previous work done in the same hospital.²³ The figure of 10.9% is low compared to other studies.^{24, 25} This might probably be due to the fact that myringotomy was not performed in these patients under review and cultures were obtained only from patients with discharging ears. The microbiology of acute otitis media in children infected with HIV is similar to the microbiology of acute otitis media in normal children.^{1, 3, 16} Compared to the control patients, the HIV-infected children presented more with chronic otitis media. This was reflected in the organisms isolated from the ear swabs, with a predominance of *Klebsiella spp*, *Proteus spp*, *Staphylococcus aureus* and *Pseudomonas spp*. Their HIV-negative counterparts with a preponderance of acute otitis media, followed by the chronic form, had a yield mainly of *Streptococcus spp*, with fewer *Klebsiella* and *Pseudomonas spp*. *Staphylococcus aureus* is significantly more frequent in otitis media diagnosed in severely immunosuppressed stages of infection with HIV.¹⁶ It has been observed that chronic suppurative otitis media characterized by persistent otorrhoea through a perforated tympanic membrane, is usually attributable to *Pseudomonas aeruginosa*, staphylococci or *Proteus spp*.^{16, 26 - 29} All the bacterial isolates were fully sensitive to the Quinolones.

. High sensitivity to quinolones was noted in other studies.^{5 7, 29} Another study in this environment also buttresses this observation.³⁰ Even though the quinolones have restricted use in paediatric practice trials of their use in treatment of otitis media have been made.^{31 - 32} Only *Escherichia coli* was still sensitive to various classes of antibiotics. This obviously makes the choice of appropriate antimicrobial therapy Problematic.

A comparative analysis of the absolute lymphocyte counts of both cohorts of patients was made with a view to using the lymphocyte count as a measure of immunosuppression.²⁰ This, however, could not be validated against the CD4 percent for age gold standard for immunosuppression. This concurs with the recommendation by the current World Health Organization Guidelines for Paediatric antiretroviral therapy²¹ to avoid the use of absolute lymphocyte counts in monitoring immunosuppression.

CONCLUSION

HIV-infected children tend to have more of chronic than acute ear infections and this is reflected in the causative organisms. Similar antimicrobial sensitivity patterns apply to HIV- infected and HIV-negative children. There is a need to revisit the use of quinolones in children.

REFERENCES

- 1 Shapiro NL, Novelli V. Otitis media in children with vertically-acquired HIV infection: the Great Ormond Street Hospital experience. Int J Pediatr Otorhinolaryngol 1998; 45 (1): 69 - 75

- 2 **Marchisio P, Principi N, Sorella S, Sala E, Tornaghi R.** Etiology of acute otitis media in Human immunodeficiency virus-infected children. *Pediatr Infect Dis J* 1996; 15(1): 58-61
- 3 **Faden H.** The microbiologic and immunologic basis for recurrent otitis media in children. *Eur J Pediatr* 2001;160 (7): 407-413.
- 4 **Ndip RN, Obi MC, Obi CL, Nwawolo C, Igumbor EO, Obi AA.** Antibigram of bacterial isolates from cases of otitis media and lower respiratory tract infections. *Afr J Med Med Sci* 1995; 24 (4): 353 - 357.
- 5 **Obi CL, Enweani IB, Giwa JO.** Bacterial agents causing chronic suppurative otitis media. *East Afr Med J* 1995; 72 (6): 370 - 372.
- 6 **Oni AA, Bakare RA, Nwaorgu OG, Ogunkunle MO, Toki RA.** Bacterial agents of discharging Ears and antimicrobial sensitivity patterns in children in Ibadan, Nigeria. *West Afr J Med* 2001;20(2): 131- 135
- 7 **Nwabuisi C, Ologe FE.** Pathogenic agents of chronic suppurative otitis media in Ilorin, Nigeria *East Afr Med J* 2002; 79(4):2002
- 8 **Anifasi WB, Tumushime- Buturo C G.** Bacteriology and drug sensitivity of chronic suppurative otitis media at a central hospital in Zimbabwe. *Cent Afr J Med* 1989;35 (9) : 481- 483.9.
9. **Hussain MA, Ali EM, Ahmed HS.** Otitis media in Sudanese children : presentation and bacteriology . *East Afr Med J* 1991; 68 (9): 679-685.
10. **Melaku A, Lulseged S.** Chronic suppurative otitis media in a children's hospital in Addis Ababa, Ethiopia. *Ethiop Med J* 1999; 37 (4): 237 -246.
- 11 **Huebner RE, Wasas AD, Hockman M, Klugman KP.** ENT Study Group. Bacterial aetiology of non-resolving otitis media in South African children. *J Laryngol Otol* 2003; 117(3): 169 - 172
12. **Jones M, Wilson L, Malis D.** Otitis media. *eMedicine* September 21 2004 at <http://www.emedicine.com/ped/topic1689.htm>
- 13 **Henderson SO, Kennedy PL.** Pediatric otitis media. *eMedicine* September 20 2004 at <http://www.emedicine.com/emerg/topic393.htm>
14. **Church JA.** HIV disease in children: the many ways it differs from the disease in adults. *Postgrad Med* 2000; 107 (4): 163 - 182.
- 15 **Church JA.** Clinical aspects of HIV infection in children. *Pediatr Ann* 1993; 22 (7): 417 - 427.
- 16 **Wald ER, Dashefsky B.** Otitis Media and Sinusitis in Patients with HIV Infection. In: *Pediatric AIDS: The Challenge of HIV Infection in Infants, Children, and Adolescents.* Pizzo PA, Wilfert CM, eds. 3rd ed. Philadelphia: J.B. Lippincott, 1998; 127 - 137
17. **Barnett ED, Klein JO, Pelton SI, Luginbuhl LM.** Otitis media in children born to human immunodeficiency virus-infected mothers. *Pediatr Infect Dis J* 1992; 11: 360 - 364.
- 18 **Chen AY, Ohlms LA, Stewart MG, Kline MW.** Otolaryngologic disease progression in children with human immunodeficiency virus infection. *Arch Otolaryngol Head Neck Surg* 1996; 122: 1360 - 1363
19. National Committee for Clinical laboratory standards. *Performance standards for antimicrobial disk susceptibility tests.* 6th Ed. Approved standard M2 A6 (M100 S7) National Committee for Clinical Laboratory Standards. Wayne. Pa. 1997
20. African Network for the Care of Children Affected by AIDS (ANECCA). *Handbook on Paediatric AIDS in Africa.* 2nd Ed. 2004
21. World Health Organization. *Interim WHO Clinical Staging of HIV/AIDS and HIV/AIDS Case definitions for Surveillance.* African Region. 2005: 1 42

- 22 **Calles NR, Evans D, Terlonge D.** Pathophysiology of the Human Immunodeficiency Virus. In: HIV Curriculum for the Health Professional. Baylor International. Pediatric AIDS Initiative. Baylor College of Medicine; 2006: 18.
23. **Ugochukwu EF.** Clinical spectrum of Paediatric HIV in Nnewi, Nigeria. West Afr J Med 2006; 25(1): 10-14.
- 24 **Singh A, Georgalas C, Patel N, Papesch M.** ENT presentations in children with HIV infection. Clin Otolaryngol Allied Sci 2003; 28(3): 240-243
- 25 **Hadfield PJ, Birchall MA, Novelli V, Bailey CM.** The ENT manifestations of HIV infection in children. Clin Otolaryngol Allied Sci 1996; 21 (1): 30- 36.
- 26 **Nakagawa T, Yadohisa O, Komune S, Uemura T.** A 16-year survey of changes in bacterial Isolates associated with chronic suppurative otitis media. Eur Arch Otorhinolaryngol 1994; 251 Suppl 1: S27-32.
- 27 **Attallah MS.** Microbiology of chronic suppurative otitis media with cholesteatoma. Saudi Med J 2000; 21 (10): 924- 927.
- 28 **Loy AH, Tan AL, Lu PK.** Microbiology of chronic suppurative otitis media in Singapore. Singapore Med J 2002: 43 (6): 296-299
- 29 **Aslam MA, Ahmed Z, Azim R.** Microbiology and drug sensitivity patterns of chronic suppurative otitis media. J Coll Phy Surg Pak 2004; 14 (8) : 459-461.
- 30 **Ugochukwu EF.** Bacterial isolates in neonatal infections. Nig Med Pract 2003; 44 (3): 56-58.
31. **Van Hasselt P, Van Kregten E.** Treatment of chronic suppurative otitis media with ofloxacin in hydroxypropyl methyl cellulose ear drops: a clinical/bacteriological study in a rural area of Malawi. Int J Pediatr Otorhinolaryngol 2002; 63 (1): 49-56.
32. **Fombeur JP, Barrault S, Koubbi G, Laurier JN, et al.** Study of the efficacy and safety of ciprofloxacin in the treatment of chronic otitis. Chemotherapy 1994; 40 Suppl 1 : 29-34